Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.49 EUR
Change Today +0.03 / 0.67%
Volume 2.5K
BIOBV On Other Exchanges
Symbol
Exchange
Helsinki
As of 11:29 AM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

biohit oyj-b (BIOBV) Snapshot

Open
€4.47
Previous Close
€4.46
Day High
€4.49
Day Low
€4.42
52 Week High
02/24/15 - €7.14
52 Week Low
07/2/15 - €4.42
Market Cap
61.9M
Average Volume 10 Days
11.3K
EPS TTM
€-0.31
Shares Outstanding
11.3M
EX-Date
04/15/15
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOHIT OYJ-B (BIOBV)

Related News

No related news articles were found.

biohit oyj-b (BIOBV) Related Businessweek News

No Related Businessweek News Found

biohit oyj-b (BIOBV) Details

Biohit Oyj, a biotechnology company, manufactures diagnostics products and diagnostics analysis systems for use in research institutions, and healthcare and industrial laboratories worldwide. Its diagnostic tests product range includes the blood-sample based GastroPanel test for diagnosing diseases of the stomach and associated risks; quick tests for the diagnosis of lactose intolerance, Helicobacter pylori infection, and Celiac disease; and ColonView for the early detection of fecal occult blood. The company’s diagnostic tests are also used for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, and gastroesophageal reflux disease, as well as deficiencies of vitamin B12, calcium, and iron. In addition, it provides acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, the company produces monoclonal antibodies for human gastric biomarkers, phytoestrogen genistein, human extracellular matrix components, human integrins, human endothelial cell surface markers, human neurotransmitter substances, human cytoskeletal polypeptides, human spectrins, and phytoestrogen. Additionally, the company provides microplate readers and strip washers for diagnostics, research, and clinical laboratory instrumentation; and electronic and mechanical pipettes, and disposable pipette tips, as well as analyses carcinogenic acetaldehyde in foodstuff, and non-alcoholic and alcoholic beverages. Biohit Oyj was founded in 1988 and is headquartered in Helsinki, Finland.

51 Employees
Last Reported Date: 05/7/15
Founded in 1988

biohit oyj-b (BIOBV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biohit oyj-b (BIOBV) Key Developments

Biohit Oyj Reports Unaudited Consolidated Earnings for the First Quarter Ended March 31, 2015

Biohit Oyj reported unaudited consolidated earnings for the first quarter ended March 31, 2015. For the period, the company’s net sales were €1.2 million against €0.9 million a year ago. Loss before tax was €0.9 million against €1.0 million a year ago. Loss for the period from continuing operations was €0.9 million against €1.0 million a year ago. Loss for the period was €0.9 million against income of €2.2 million a year ago. Undiluted loss per share from continuing operations was €0.07 against €0.07 a year ago. Net cash flow used in operating activities was €1.1 million against €0.6 million a year ago. Investments in tangible and intangible assets were €0.1 million against €0.1 million a year ago. Operating loss from continuing operations was €1.0 million against €1.2 million a year ago.

Biohit Oyj Elects Osmo Suovaniemi as Chairman of the Board of Directors

Biohit Oyj’s Board of Directors has in its meeting April 20, 015 elected Mr. Osmo Suovaniemi as the Chairman of the Board of Directors.

Biohit Oyj, Board Meeting, Apr 20, 2015

Biohit Oyj, Board Meeting, Apr 20, 2015. Agenda: To elect Mr. Osmo Suovaniemi as the chairman of the board of directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOBV:FH €4.49 EUR +0.03

BIOBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOBV.
View Industry Companies
 

Industry Analysis

BIOBV

Industry Average

Valuation BIOBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHIT OYJ-B, please visit www.biohithealthcare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.